Sage Therapeutics scraps development of rare disease drug after it fails mid-stage study (updated)

Sage Therapeutics

20/11/2024 11:54

(Adds shares in paragraph 2, details throughout)
       Nov 20 (Reuters) - Sage Therapeutics  SAGE.O  will stop
development of its experimental drug to treat cognitive
impairment in patients with Huntington's disease after it failed
a mid-stage study, the drug developer said on Wednesday.
    The drug, dalzanemdor, did not significantly improve
cognitive function in patients compared to placebo after 84
days, failing to meet the main goal of the study.
    The drug also failed to achieve "statistical significance"
in secondary goals of the study, Sage said. 
    Huntington's disease is an inherited disorder that causes
nerve cells in parts of the brain to gradually break down and
die.

 (Reporting by Mariam Sunny in Bengaluru; Editing by Shinjini
Ganguli and Sriraj Kalluvila)
 ((Mariam.ESunny@thomsonreuters.com;))